Caribou Biosciences Inc (CRBU) Stock Price, Quote & News

Company Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Ho...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 982 6030

Website: cariboubio.com

Address:

2929 7th Street, Suite 105, Berkeley, United States

Jidane Aug. 22 at 9:10 PM

$CRBU Please don’t get me wrong. I believe stock is extremely undervalued. Just expect the dilution in mind.

0 · Reply

Jidane Aug. 22 at 8:13 PM

$CRBU We authorized them to be able to issue 300,000,000 shares.

0 · Reply

Jidane Aug. 22 at 8:10 PM

$CRBU They already issued 9 million shares ATM, and raised $17MILLION. That’s how they extended their cashflow to 2027 2nd half.

1 · Reply

smallcapexpert Aug. 21 at 2:42 PM

$CRBU running 📈🔥 2,20$ soon

0 · Reply

Windytimes Aug. 21 at 1:27 PM

$CRBU please announce a partnership soon that’s not dilutive to existing shareholders

0 · Reply

vu_jade Aug. 20 at 7:33 PM

$CRBU too cheap to not buy again

1 · Reply

HughGeez Aug. 19 at 7:40 PM

$CRBU Well put. Shorting a company trying (and so far succeeding) to create accessible cancer therapies is really the lowest of the low.

0 · Reply

Windytimes Aug. 19 at 7:18 PM

$CRBU let me be the first to say fuck you to those that are shoring this company.

1 · Reply

Windytimes Aug. 19 at 7:17 PM

$CRBU this PA is interesting. Nobody believes in this company or they are forcing everyone out so this can rip higher when they announce positive data or news around funding…

0 · Reply

RocroBio Aug. 19 at 6:18 PM

$CRBU $MRK $MRNA $NTLA bio season👀

0 · Reply

Caribou Biosciences reports Q2 EPS (24c), consensus (31c)

2026-08-16T13:45:19.000Z - 8 days ago

Caribou Biosciences price target lowered to $5 from $6 at BofA

Aug 13, 2026, 4:05 PM EDT - 10 days ago

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Caribou Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Caribou Biosciences Earnings release: Q2 2026

Jun 30, 2026, 10:00 AM EDT - 7 weeks ago

Caribou Biosciences Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 17, 2026, 10:30 AM EDT - 2 months ago

Caribou Biosciences Transcript: AGM 2026

2026-06-11T13:03:22.000Z - 2 months ago

Caribou Biosciences presents ANTLER trial results at EHA

Jun 11, 2026, 8:01 AM EDT - 2 months ago

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Caribou Biosciences Slides: Corporate presentation

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Proxy statement: Proxy filing

Jun 4, 2026, 2:35 PM EDT - 2 months ago

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 3 months ago

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 19, 2026, 12:30 PM EDT - 3 months ago

Caribou Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 3 months ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 11:40 AM EDT - 3 months ago

Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 9:30 AM EDT - 3 months ago

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

2026-05-11T10:25:24.000Z - 3 months ago

Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright

May 7, 2026, 4:05 PM EDT - 3 months ago

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 7:00 AM EDT - 3 months ago

Caribou Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Caribou Biosciences Earnings release: Q1 2026

May 5, 2026, 4:05 PM EDT - 3 months ago

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

May 1, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Caribou Biosciences Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T12:14:17.000Z - 6 months ago

Caribou Biosciences price target raised to $13 from $11 at Evercore ISI

2026-03-05T21:28:29.000Z - 6 months ago

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

Mar 5, 2026, 4:05 PM EST - 6 months ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 3:00 PM EST - 6 months ago

Caribou Biosciences Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 6 months ago

Caribou Biosciences Earnings release: Q4 2025

Feb 19, 2026, 10:45 AM EST - 6 months ago

Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 17, 2026, 8:00 AM EST - 6 months ago

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 12, 2026, 4:05 PM EST - 6 months ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST - 7 months ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

2026-02-02T21:25:29.000Z - 7 months ago

Caribou Biosciences initiated with a Buy at Clear Street

2026-01-06T15:15:25.000Z - 8 months ago

Caribou Biosciences price target lowered to $6 from $8 at BofA

Dec 6, 2025, 7:30 AM EST - 9 months ago

Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2025, 7:00 AM EST - 9 months ago

Caribou Biosciences Slides: Corporate Presentation

Dec 2, 2025, 8:45 AM EST - 9 months ago

Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 4:05 PM EST - 9 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

2025-11-12T22:25:13.000Z - 10 months ago

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Nov 12, 2025, 4:05 PM EST - 10 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Quarterly report: Q3 2025

2025-11-05T11:21:02.000Z - 10 months ago

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

2025-11-03T15:15:34.000Z - 10 months ago

Caribou Biosciences price target raised to $8 from $5 at Citi

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Transcript: Study Result

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Press release: Study Result

Nov 3, 2025, 8:00 AM EST - 10 months ago

Caribou Biosciences Slides: Study Result

2025-11-03T12:22:51.000Z - 10 months ago

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

2025-11-03T12:15:12.000Z - 10 months ago

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

Nov 3, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 10 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 2, 2025, 4:00 PM EST - 10 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Sep 3, 2025, 2:30 PM EDT - 1 year ago

Caribou Biosciences Transcript: Citi's Biopharma Back to School Conference

Aug 30, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Slides: Corporate Presentation

Aug 25, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Caribou Biosciences Quarterly report: Q2 2025

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 13, 2025, 5:35 PM EDT - 1 year ago

Caribou Biosciences Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Registration statement: Registration Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

May 6, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Caribou Biosciences Proxy statement: Proxy Filing

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Jidane Aug. 22 at 9:10 PM

$CRBU Please don’t get me wrong. I believe stock is extremely undervalued. Just expect the dilution in mind.

0 · Reply

Jidane Aug. 22 at 8:13 PM

$CRBU We authorized them to be able to issue 300,000,000 shares.

0 · Reply

Jidane Aug. 22 at 8:10 PM

$CRBU They already issued 9 million shares ATM, and raised $17MILLION. That’s how they extended their cashflow to 2027 2nd half.

1 · Reply

smallcapexpert Aug. 21 at 2:42 PM

$CRBU running 📈🔥 2,20$ soon

0 · Reply

Windytimes Aug. 21 at 1:27 PM

$CRBU please announce a partnership soon that’s not dilutive to existing shareholders

0 · Reply

vu_jade Aug. 20 at 7:33 PM

$CRBU too cheap to not buy again

1 · Reply

HughGeez Aug. 19 at 7:40 PM

$CRBU Well put. Shorting a company trying (and so far succeeding) to create accessible cancer therapies is really the lowest of the low.

0 · Reply

Windytimes Aug. 19 at 7:18 PM

$CRBU let me be the first to say fuck you to those that are shoring this company.

1 · Reply

Windytimes Aug. 19 at 7:17 PM

$CRBU this PA is interesting. Nobody believes in this company or they are forcing everyone out so this can rip higher when they announce positive data or news around funding…

0 · Reply

RocroBio Aug. 19 at 6:18 PM

$CRBU $MRK $MRNA $NTLA bio season👀

0 · Reply

RocroBio Aug. 19 at 6:16 PM

$CRBU lagging peers per usual 🥱

0 · Reply

NicaInvest85 Aug. 19 at 4:13 PM

$CRBU we have a long way to go but hopefully Jennifer Doudna reins the company Moderna: A multi-billion-dollar commercial enterprise with globally distributed approved products. Caribou Biosciences: A clinical-stage biotechnology with treatments actively moving through early human clinical trials.

0 · Reply

smallcapexpert Aug. 19 at 3:48 PM

$CRBU took 35k 1,625 avg. Extremly bullish on verry good cut on costs. Strong cash on hand with upcomming partnerships! 📈

0 · Reply

ChicagoJoe20 Aug. 19 at 1:10 PM

$CRBU these technologies are fascinating. We're drilling into the human code.

0 · Reply

NicaInvest85 Aug. 19 at 12:26 PM

$CRBU $MRNA Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%. Lets go $CRBU

0 · Reply

HughGeez Aug. 18 at 11:34 AM

$CRBU I am no expert on Altimmune but didn't Altimmune drop because of mixed phase 2 results? We don't have that with CRBU. Also even though they had mixed phase 2 results the stock price is $3 with much higher market cap.

0 · Reply

cta7978 Aug. 18 at 8:13 AM

$CRBU 3 quarters "exploring financing options", then last quarter dilluting nearly 10% at low stock price (~$2.03).. I fear they are going to have to go it alone.. Don't really understand why? I held Altimmune a few years ago, everyone was hoping for a partnership or a big pharma deal after phase 2, then everything just died and they did massive dilution and screwed shareholders. They need to axe their CBO and get someone that can make a deal. This last quarters dilution at stock price lows shows real desperation.

1 · Reply

Windytimes Aug. 16 at 1:40 PM

$CRBU https://www.genengnews.com/topics/bioprocessing/allogeneic-car-t-company-prepares-to-widen-access-to-patients/?utm_campaign=41123468-GEN_Editorial%20Social&utm_content=384251436&utm_medium=social&utm_source=linkedin&hss_channel=lcp-1385856

0 · Reply

HughGeez Aug. 14 at 6:36 PM

$CRBU We are in a much better position (based on the clinical results) than we were when the stock was $10, so hopefully we should return to at least there.

1 · Reply

Jidane Aug. 14 at 4:02 PM

$CRBU No news, No update.

0 · Reply

biochirp Aug. 14 at 1:57 PM

$CRBU theres the dump to sub 1.5

2 · Reply

Facade78 Aug. 13 at 9:36 PM

$CRBU Good job ! Better results, 50% less operating expenses... Waiting for phase 3...

0 · Reply

Market Cap	177.97M
Revenue (ttm)	11.16M
Net Income (ttm)	-148.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,327.33%
Debt to Equity Ratio	0.00

Volume	498,174
Avg Vol	1,855,236
Day's Range	N/A - N/A
Shares Out	107.21M
Stochastic %K	70%
Beta	2.38
Analysts	Strong Sell
Price Target	$11.86